Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 148 participants.
Also called NCT02488252
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 148 participants
- Sponsor
- Registry
-
NCT02488252
-
- Other papers using this trial's data
- Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Hong Kong SAR China
- Registry status
- Unknown status
Technical summary
Registry record NCT02488252. Randomized; single masking; primary purpose treatment. Start 2015-07 (actual); primary completion 2021-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy
- Acronym
- SCHEMATIC
- Condition
- Diabetic Nephropathies
- Intervention (Drug)
- Semi-individualised Chinese Medicine treatment
- Intervention (Drug)
- Routine medical care (active comparator)
- Lead sponsor
- The University of Hong Kong
Record details
- Record id
cardio:ct-nct02488252- Content hash
3bfe5d62fc89eda82b7b47fc00c492c064144627f00677c42d3de456949a9c12